PST
NN
NN
Set of flashcards Details
| Flashcards | 15 |
|---|---|
| Language | Deutsch |
| Category | German |
| Level | Primary School |
| Created / Updated | 16.01.2018 / 06.03.2018 |
| Weblink |
https://card2brain.ch/box/20180116_pst
|
| Embed |
<iframe src="https://card2brain.ch/box/20180116_pst/embed" width="780" height="150" scrolling="no" frameborder="0"></iframe>
|
What are current NN business challenges and make a PST key? (4 points)
•Increasing access restrictions – every interaction counts
•Increasing competitor launches – we have to compete better
•Cost-cutting by NN and competitors – operational efficiency is key
•Increasing portfolio – need to deliver sales messages across all brands
What are the NN, NNRE, BANC total sales and OP expectations for 2018?
NN: 105 bDKK
NNRE: 22 bDKK
BANC: 5.2 bDKK Sales, 3.3 bDKK OP (72% Operating Margin)
Name all Affilates ranked by Total Sales:
1. NL: 1.127 mDKK
2. SE: 815 mDKK
3. DK: 714 mDKK
4. CH: 704 mDKK
5. FI: 484 mDKK
6. BE: 424 mDKK
7. AT: 331 mDKK
8. NO: 323 mDKK
9. IRE: 214 mDKK
What is the key commercial focus for NL in 2018? (5)
- Tresiba® basal initiation and switches in T2
- Victoza® leverage LEADER results
- Fiasp® convert and initiate (focus on pump segment)
- Ryzodeg® to receive from NovoMix®
- NovoEight® Maximise patient uptake with optimal contracting
Name the 4 main risks in NL and mitigating actions
- Start basal patients on biosimilars -> Disseminate on hypo- and dose reduction
- Extension of WGP price referencing system -> EUNC price setting immportance
- Loss of N7 sales to ACE910 -> Using smart N7 data
- Price pressure on FlexPro® in new buying round -> request market fit price
What are the 3 main DMI categories in NL?
- Sales support 11.8 mDKK (Tresiba and Fiasp)
- Events & conventions 7.3 mDKK (Fiasp and Tresiba)
- Market Access 3.3 mDKK (Victoza)
When is Ozempic planned to be launched in NL?
Q4 2018
What is the Market Access rate of Insulins vs. GLP-1 in NL?
100% vs. 11% (GPs and Specs vs. only Specs)
What is the Field Force time allocation for NL?
23 SRs in Primary care insulins (70% Tresiba® and 30% Ryzodeg® in C1 and C2 and 50% Tresiba® 50% Fiasp® in C3)
7 SRs in Secondary care insulins (50% Tresiba® and 50% Fiasp for all three cycles)
4 KAM with 60% Tresiba®, 10% Ryzodeg and 30% Fiasp®
4 SRs in secondary care GLP-1 (70% Victoza® and 30% Xultophy®)
Who are the main competitors with promotional activity in NL?
Sanofi with Toujeo (lower volume and same efficacy as Lantus) and Suliqua (convenience of device)
Lilly with Humalog (lower volume), Abasaglar (Pharmacists benefit from prescribing it) and Trulicity (Focus as add on to basal and convenience)
How many % of diagnosed patients get a prescription by a GP ni NL? And what is the ranking of treatment choice among GPs? and within insulin, what is the ranking of types?
- 86% get a Rx by GPs
- Trad. OAD, Diet&Exercise, Insulin, DPP4 and GLP-1
- Basal-Bolus, Basal only, Premix, Basal only and Fixed combo (0)
What is the treatment choice of Specs in NL? What is the ranking of therapies within insulins?
Traditional OaD, Insulin Therapy, GLP1, DPP4 and DietExercise (0)
Basal-Bolus, Basal only, Premix, Fixed combo, bolus only
What is the treatment choice of GPs and Specs for diagnosed diabetes patients in CH?
Total (350'000 diagnosed) first Diet&Exercise, DPP4, Insulin, OAD, SGLT2, GLP1
What are the Top4 Diabetes tactics in CH?
- Lunch talks Victoza abd Xultophy
- Scientific roundtables Victoza, Xultophy and Ozempic
- Joint Cardio Specs meetings scientific
- Aerzteseminare
How does the FF time allocation looks like in CH?
9 SRs with 50% Xultophy, 40% Victoza and 10% Tresiba in C1 and C2 and 30% Xultophy and 70% Ozempic
5 KAMs with equal allocation to Xultophy, Victoza, Tresiba and Fiasp in C1 an C2 and 100% in C3 for Ozempic
